Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal

BACKGROUND/AIMS: We studied the role of lysyl oxidase-like 2 (LOXL2) in collagen crosslinking and hepatic progenitor cell (HPC) differentiation, and the therapeutic efficacy of a LOXL2-blocking monoclonal antibody on liver fibrosis progression/reversal in mice. METHODS: Anti-LOXL2 antibody, control...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gut
Main Authors: Ikenaga, Naoki, Peng, Zhen-Wei, Vaid, Kahini A, Liu, Susan B, Yoshida, Shuhei, Sverdlov, Deanna Y, Mikels-Vigdal, Amanda, Smith, Victoria, Schuppan, Detlef, Popov, Yury V
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2017
Assuntos:
Hepatology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5561383/
https://ncbi.nlm.nih.gov/pubmed/28073888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2016-312473
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados